CJC-1295 and Ipamorelin: a file assembled from other files.
The names on the study matter. Much of the combination argument belongs to hexarelin, GHRP-2 or GHRP-6.
What is CJC 1295 ipamorelin?
It is a pairing of two growth-hormone secretagogues, compounds that prompt hormone release. Ipamorelin acts at the ghrelin receptor; CJC-1295 acts at the GHRH receptor. The distinction makes the combination pharmacologically plausible, because the pathways are complementary rather than identical.
Ipamorelin produced a brief growth-hormone pulse after intravenous administration. CJC-1295, studied separately in its long-acting DAC form, produced 2- to 10-fold growth-hormone increases for six-plus days and 1.5- to 3-fold IGF-1 elevation after a single subcutaneous dose in healthy adults. The separate experiments supply the parts of the argument. The rationale earns some credit from me; the unmeasured outcome earns none.
Hexarelin owns the striking synergy result
In healthy men given hexarelin with GHRH, peak growth-hormone secretion exceeded the arithmetic sum of the separate responses, with p=0.001. That is genuine synergy, more than an additive effect. The investigators used hexarelin. The synergism faded with repeated boluses 60–120 minutes apart.
I take the fading response as a reason to read the whole entry. A peak result does not carry its own duration, and a shared receptor does not make different peptides the same tested compound.
GHRP-2 and GHRP-6 fill other cards
The 30-day GHRP-2 and GHRH work in older men and women supports greater hormone output from the combination than from either alone, with sustained IGF-1 and no tachyphylaxis over the tested interval. A 34-hour GHRP-6 infusion in healthy men amplified responses to superimposed GHRH boluses. Another GHRP-2 and GHRH study found that chronic pre-treatment could turn an additive response into a synergistic one.
These are human findings and deserve their place in the argument. I won't erase the compound names when carrying a result into a new argument: none of these studies tested the CJC-1295 and ipamorelin pair. Their hormone measurements also do not demonstrate better sleep, fat loss or faster training recovery from that pair.
Does CJC-1295 ipamorelin work?
The 2026 orthopaedic narrative review describes improved maximal muscle tetanic tension in a mouse model of glucocorticoid-induced muscle loss. It measured muscle force under experimental stimulation in animals. Human strength and recovery outcomes remain untested for this pair. The 2026 sports-medicine review emphasizes scarce rigorous human safety data and the potential for serious harm among unapproved peptide therapies.
No controlled human outcome trial has demonstrated a wellness benefit for this specific combination. I regard the animal finding as a reason for an appropriately designed human study. The popular file contains a rationale, related human hormone results and an animal combination result. It still lacks the direct human outcome entry.
Ipamorelin vs tesamorelin
Tesamorelin is a stabilized GHRH analog with an FDA-approved indication for reducing excess abdominal fat in HIV-associated lipodystrophy. Ipamorelin is a ghrelin-receptor agonist with no approved drug indication and a published efficacy trial that missed its endpoint. The comparison crosses both a receptor distinction and a development-history distinction.
The same caution applies to adding sermorelin: it is on the GHRH side too. Adding both sermorelin and CJC-1295 would largely duplicate that receptor pathway. There is no controlled trial of the three-way combination, or of tesamorelin with ipamorelin, to establish safety and benefit. The sermorelin comparison lays out those different histories without ranking the compounds as personal treatment choices.